CompletedPHASE2, PHASE3NCT02786836

13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF

Studying Acute liver failure

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Texas Southwestern Medical Center
Principal Investigator
Robert J. Fontana, MD
University of Michigan
Intervention
13C-Methacetin(drug)
Enrollment
76 enrolled
Eligibility
18-80 years · All sexes
Timeline
20162019

Study locations (11)

Collaborators

Medical University of South Carolina · University of Michigan · Meridian Bioscience, Inc. · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02786836 on ClinicalTrials.gov

Other trials for Acute liver failure

Additional recruiting or active studies for the same condition.

See all trials for Acute liver failure

← Back to all trials